[Gene therapy for breast cancer]

Area of Science:

• Oncology
• Gene Therapy
• Hematology

Background:

• Advanced or relapsed breast cancer prognosis remains poor despite chemotherapy and endocrine therapy.
• Gene therapy presents a promising therapeutic avenue for advanced breast cancer.
• Current gene therapy strategies include oncogene suppression, immune enhancement, suicide gene transduction, and drug resistance gene transfer.

Purpose of the Study:

• To evaluate the safety and efficacy of multidrug resistance gene (MDR1) therapy in patients with advanced or relapsed breast cancer.
• To assess the in vivo enrichment of MDR1-transduced cells following high-dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT).

Main Methods:

• A clinical study involving advanced or relapsed breast cancer patients undergoing high-dose chemotherapy and autologous PBSCT with MDR1-transduced hemopoietic stem cells.
• Post-transplantation treatment with docetaxel to promote enrichment of MDR1-transduced cells.
• Monitoring for complete remission and adverse effects.

Main Results:

• Two patients were treated, both exhibiting in vivo enrichment of MDR1-transduced cells after docetaxel treatment post-PBSCT.
• Both patients achieved complete remission.
• No apparent adverse effects were observed from the MDR1 gene transduction.

Conclusions:

• MDR1 gene therapy combined with high-dose chemotherapy, PBSCT, and docetaxel is a potentially effective treatment for advanced or relapsed breast cancer.
• This approach demonstrated successful in vivo cell enrichment and achieved complete remission in treated patients.
• The treatment appears safe with no significant adverse effects related to MDR1 gene transduction.